Bioverativ Inc. Common Stock
BIVV
BIVV was delisted on the 8th of March, 2018.
2 hedge funds and large institutions have $27K invested in Bioverativ Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 449 closing their positions.
100% less funds holding
Funds holding: 459 → 2 (-457)
100% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 449
100% less funds holding in top 10
Funds holding in top 10: 5 → 0 (-5)
100% less capital invested
Capital invested by funds: $5.76B → $27K (-$5.76B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACS
Archford Capital Strategies
Swansea,
Illinois
|
+$2.28K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$585M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$497M |
| 3 |
Primecap Management
Pasadena,
California
|
-$411M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$274M |
| 5 |
State Street
Boston,
Massachusetts
|
-$232M |
BIVV Hedge Fund Activity: Q1 2018 in Review
2 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Bioverativ Inc. Common Stock (BIVV) for Q1 2018, worth a combined $27K — down 100% from $5.76B a quarter earlier.
Sellers outnumbered buyers: 449 funds closed out of BIVV and 1 opened new positions — a net loss of 448 holders — while 0 trimmed existing stakes and 0 added.
The largest buyer was Archford Capital Strategies, opening a new position worth an estimated $2.28K. The largest seller was BlackRock, exiting entirely with an estimated $585M sold.
- 2 institutional investors held Bioverativ Inc. Common Stock (BIVV) as of Q1 2018, down from 459 in Q4 2017.
- Funds reported $27K of Bioverativ Inc. Common Stock stock for Q1 2018, down 100% quarter-over-quarter.
- 1 fund opened new Bioverativ Inc. Common Stock positions in Q1 2018 and 449 closed out, a net change of -448 holders.
- The largest Bioverativ Inc. Common Stock buyer in Q1 2018 was Archford Capital Strategies, an estimated $2.28K added.
- The largest Bioverativ Inc. Common Stock seller in Q1 2018 was BlackRock, an estimated $585M sold.
Based on aggregated 13F filings for Q1 2018.